Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020: Discontinuation of Drugs Under Development Leading to Substantial Loss in Revenue - Research and Markets

Research and Markets
Posted on: 17 Nov 16

Research and Markets has announced the addition of the "Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020" report to their offering.

The global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period. The report also includes a discussion of the key vendors operating in this market.

Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Amgen
  • F. Hoffmann-La Roche
  • Pfizer

Other prominent vendors

  • AstraZeneca
  • Avaxia Biologics
  • Biogen Idec
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Eli Lilly
  • Enlivex Therapeutics
  • Gilead Sciences
  • Immune Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe Pharma
  • Neovacs
  • Prometheus Laboratories
  • Sandoz
  • Sanofi
  • Swedish Orphan Biovitrum
  • Takeda Pharmaceuticals
  • UCB

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Autoimmune and inflammatory diseases

Part 06: Pipeline portfolio

Part 07: Market landscape

Part 08: Market segmentation by type of disease

Part 09: Market segmentation by molecule type

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Key vendor analysis

Part 18: Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 17/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.